GlassScriptPhysician profile
Anisha Thadani
NPI 1346403920
$6,959.86
in general payments reported to CMS, 2019-2025
35 companies · $2,395 in 2025
The $2,395 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $138 · 2021: $305 · 2022: $588 · 2023: $883 · 2024: $1,904 · 2025: $2,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,161 · Education: $21.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,161.26 |
| Education | $21.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,326.43 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $827.69 | 2021-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $538.22 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $496.87 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.41 | 2019-2025 | Xifaxan, Relistor |
| Lilly USA, LLC | $308.46 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $284.07 | 2022-2025 | Ibsrela |
| Celgene Corporation | $268.46 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $254.97 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $238.34 | 2021-2022 | |
| Medtronic, INC. | $201.14 | 2022-2023 | Bravo |
| Phathom Pharmaceuticals, INC. | $159.97 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $156.28 | 2021-2024 | |
| Covidien LP | $141.38 | 2019 | |
| Boston Scientific Corporation | $137.36 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $130.25 | 2023-2024 | Dupixent |
| Genzyme Corporation | $125.34 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $121.07 | 2022-2025 | Rebyota |
| Terumo Medical Corporation | $115.36 | 2019 | |
| Braintree Laboratories, INC. | $105.88 | 2023-2025 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $82.69 | 2025 | Rezdiffra |
| Celltrion USA INC. | $78.52 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $78.27 | 2023-2025 | Sucraid |
| Merck Sharp & Dohme LLC | $73.67 | 2023-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $53.91 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $41.60 | 2023 | |
| Novo Nordisk INC | $36.44 | 2024-2025 | Wegovy |
| Evoke Pharma, INC. | $30.47 | 2024 | |
| Pharmacosmos Therapeutics INC. | $30.05 | 2025 | Monoferric |
| Aimmune Therapeutics, INC. | $22.18 | 2024 | |
| Azurity Pharmaceuticals, INC. | $20.90 | 2025 | Suflave |
| Amgen INC. | $20.35 | 2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $15.98 | 2023 | Givlaari |
| Ironwood Pharmaceuticals, INC | $14.90 | 2020 | |
| W. L. Gore & Associates, INC. | $13.98 | 2023 | Gore Cardioform Septal Occluder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anisha Thadani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.